Opinion

Video

Evolving Treatment Paradigm in HER+ Breast Cancer: Future Directions

Key opinion leaders anticipate future developments in HER2-positive breast cancer, and on the potential for translating therapeutic advances from the metastatic landscape into early-stage disease management.

Related Videos
Adrienne G. Waks, MD,
David Rimm, MD, PhD
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
This series features 2 KOLs
This series features 2 KOLs
Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: primary results from DESTINY-Breast06
A panel of 3 experts on CLL
A panel of 3 experts on CLL
4 KOLs are featured in this series.